key: cord-0877880-qs10a7gb
authors: Shoar, Saeed
title: D-dimer and Poor Clinical Outcome in Patients with COVID-19: Lessons from Meta-analysis of Case-Control Studies
date: 2021-01-12
journal: Heart Lung
DOI: 10.1016/j.hrtlng.2021.01.004
sha: 187e70d453a571b98b2a485244f2ef81e7a8a678
doc_id: 877880
cord_uid: qs10a7gb

nan

The included studies are retrospective cohorts in which the underlying comorbidities in patients with COVID-19 might not have evenly distributed between case and control groups or adequately adjusted for. Such a heterogeneity might simply be transferred to the pooled effect size rendered by this meta-analysis, which is clearly obvious from such a high heterogeneity (I 2 = 98%) across the included studies. For instance, kidney function before developing COVID-19 and during the course of hospital stay is an important predictor of clinical outcome and variations in serum level of D-dimer [2] .

As depicted in their summary table, the composite endpoint of this meta-analysis is a combination of the primary endpoint by the included studies. This might be a major source of large heterogeneity across the pooled analysis as is also evident from the wide confidence interval calculated for the median level of D-dimer in each study. One potential way to reduce such a heterogeneity is to perform sub-group analysis for each outcome measure or including studies with similar composite endpoint into the same pooled analysis. Also, one might question the reliability of pooling different serum levels of D-dimer for different outcome measures of inhospital mortality, ICU admission, and ARDS and referring to it as a composite endpoint [3] .

Although D-dimer is an important marker in predicting coagulopathy and poor clinical outcome in patients with COVID-19, cardiovascular instability and other metabolic derangements play an undeniably pivotal role in determining the clinical outcome [4] . For this reason, D-dimer does not seem to be an independent predictor of poor clinical outcome or mortality in patients with COVID-19, or at least cannot be concluded solely by pooling the data from retrospective studies with different endpoints, variable underlying patient characteristics, and unknown provided treatment at the index institutions. Not to mention that the clinical management of patients with COVID-19 has substantially evolved since early 2020 and that also has a huge impact on the patient outcome.

There is no conflict of interest in any forms.

No funds have been received in any forms.

The association of D-dimers with mortality, intensive care unit admission or acute respiratory distress syndrome in patients hospitalized with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Renal Function-Adjusted D-Dimer Levels in Critically Ill Patients With Suspected Thromboembolism

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19